Melanoma-associated antigen 3 peptide presented by HLA class I (MAGE-A3/HLA complex)

Melanoma-associated antigen 3 (MAGE-A3) is a prominent cancer-testis antigen (CTA) that is highly expressed in a variety of solid tumors, including melanoma and non-small cell lung cancer, but is restricted to the testis and placenta in healthy individuals [5, 8, 16]. Because these normal tissues lack HLA class I expression, the MAGE-A3 peptide presented by HLA class I (such as the HLA-A*01-restricted EVDPIGHLY or HLA-A*02-restricted KVAELVHFL peptides) serves as a highly specific target for T-cell-mediated immunotherapy [7, 12, 15]. Therapeutic approaches targeting this complex include T-cell receptor (TCR)-engineered T-cell therapies and cancer vaccines designed to stimulate a cytotoxic T-lymphocyte response against tumor cells [1, 6, 14]. However, the clinical development of MAGE-A3-targeted therapies has faced significant hurdles, most notably fatal off-target toxicities. These toxicities resulted from TCR cross-reactivity with similar peptides, such as MAGE-A12 in the brain and the muscle protein Titin in the heart, leading to severe neurological and cardiovascular damage [2, 3, 21]. Despite these challenges, MAGE-A3 remains a critical target in oncology, with ongoing research focusing on developing high-affinity TCRs with improved specificity to minimize off-target risks [10, 13].

Other names

MAGE-A3/HLA-A1 complexMAGE-A3/HLA-A2 complexMAGE-A3 peptide-MHC complexAntigen MZ2-DCancer/testis antigen 1.3CT1.3MAGE-3 antigen

T-cell receptor (TCR) binding, T-cell mediated cytotoxicity, and induction of antigen-specific immune response